BioCryst Pharmaceuticals
BCRX
241 hedge funds and large institutions have $1.08B invested in BioCryst Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 83 increasing their positions, 69 reducing their positions, and 38 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 69
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
18% more capital invested
Capital invested by funds: $915M → $1.08B (+$162M)
13% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 38
1% more funds holding
Funds holding: 238 → 241 (+3)
3% less call options, than puts
Call options by funds: $8.76M | Put options by funds: $9.04M
2.83% less ownership
Funds ownership: 87.32% → 84.49% (-2.8%)
Top Buyers
| 1 |
CP
Caligan Partners
New York
|
+$21.2M |
| 2 |
DM
Deerfield Management
New York
|
+$17.3M |
| 3 |
Alkeon Capital Management
New York
|
+$16.6M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$12.7M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$10.3M |
Top Sellers
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$55.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$44.9M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$17.2M |
| 4 |
Citigroup
New York
|
-$11.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.21M |
BCRX Hedge Fund Activity: Q2 2024 in Review
241 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2024, worth a combined $1.08B — up 18% from $915M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new BCRX positions and 38 closed out — a net gain of 5 holders — while 83 added to existing stakes and 69 trimmed.
The largest buyer was Caligan Partners, adding an estimated $21.2M. The largest seller was Baker Bros. Advisors, cutting an estimated $55.5M.
- 241 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2024, up from 238 in Q1 2024.
- Funds reported $1.08B of BioCryst Pharmaceuticals stock for Q2 2024, up 18% quarter-over-quarter.
- 43 funds opened new BioCryst Pharmaceuticals positions in Q2 2024 and 38 closed out, a net change of +5 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2024 was Caligan Partners, an estimated $21.2M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2024 was Baker Bros. Advisors, an estimated $55.5M sold.
Based on aggregated 13F filings for Q2 2024.